TAG:
sequencing technology
Illumina to Pay $1.2 Billion to Acquire Pacific Biosciences
By Joseph Burns | From the Volume XXV No. 17 – December 3, 2018 Issue
IT’S AN ACQUISITION THAT BRINGS TOGETHER two different gene sequencing technologies into one firm. On Nov. 1, Illumina, Inc., announced an agreement to acquire Pacific Biosciences (PacBio) for $1.2 billion. This deal will bolster Illumina’s already-dominant posit…
March 26, 2018 Intelligence: Late Breaking Lab News
By Robert Michel | From the Volume XXV No. 5 – March 26, 2018 Issue
On March 6, one of the lab industry’s long-serving executives and consultants, Jack Mattice, PhD, of Vancouver, Wash., died from flu complications. He was 77 years old. Mattice earned a PhD in medical microbiology from University of Oregon. Within a few years, he was handling mark…
Whole Genome Sequencing Is Poised for Clinical Use
By Robert Michel | From the Volume XXI No. 5 – April 7, 2014 Issue
CEO SUMMARY: Pathologists and clinical lab managers interested in following the advances in use of whole human genome sequencing for clinical purposes should follow the money. Within weeks of obtaining FDA clearance for its MiSeqDx system and reagents, Illumina had inked major agreements …
September 17, 2012 “Intelligence: Late Breaking Lab News”
By Robert Michel | From the Volume XIX No. 13 – September 17, 2012 Issue
Exome sequencing testing for cancer patients is now offered by the Cancer Genetics Laboratory at Baylor College of Medicine (BCM) in Houston, Texas. This clinical testing will be performed using next-generation gene sequencing technology. Pathologists at Baylor are among the first in…
Exome Sequencing Next “Big Thing” for Diagnosis
By Joseph Burns | From the Volume XIX No. 5 – April 2, 2012 Issue
CEO SUMMARY: For disease diagnostics, exome sequencing is not yet routine, but geneticists are getting close. Using this technology, researchers read those parts of the human genome where about 85% of disease-causing mutations reside. By looking only at the regions that encode proteins—…
Roche Offers $5.7 Billion To Acquire Illumina Inc.
By Joseph Burns | From the Volume XIX No. 2 – January 30, 2012 Issue
CEO SUMMARY: Once again, Roche is hunting for gene sequencing and gene analysis technology that can support its goal of being a world leader in gene-based therapeutics and clinical lab testing that utilizes gene tests and molecular diagnostics. Last week, Roche launched a hostile stock te…
Whole Genome Sequencing: Is It Ready for Prime Time?
By Robert Michel | From the Volume XVII No. 16 – November 15, 2010 Issue
CEO Summary: Pathologists at Beth Israel Deaconess Medical Center in Boston, Massachusetts, in a collaboration with GenomeQuest, Inc., will produce whole human genome sequences of patient tumors and other specimens. These whole genome sequences will be studied to learn what diagn…
Costs Falling Swiftly for Whole Genome Sequence
By Robert Michel | From the Volume XVI No. 16 – November 23, 2009 Issue
CEO SUMMARY: Several companies want to be first to achieve the holy grail in sequencing: an accurate whole human genome sequence produced in an hour for $1,000. Complete Genomics announced earlier this month that it could sequence the full human genome for a materials cost of $4,400 (not …
Rapid Genome Sequencing Predicted by Mid-2009
By Robert Michel | From the Volume XV No. 14 – October 20, 2008 Issue
CEO SUMMARY: In the same way that the Human Genome Project was disrupted by the entry of C. Craig Venter and Perkin-Elmer in what was then a 15-year, $3 billion project, now Complete Genetics of Mountain View, California, is disrupting the race to the $1,000 human genome sequence. Develop…
October 16, 2006 “Intelligence: Late Breaking Lab News”
By Robert Michel | From the Volume XIII No. 14 – October 16, 2006 Issue
American Esoteric Laboratories, Inc. today announced that it has signed an extended, five-year contract to provide reference and esoteric testing services to the 14-hospital Baptist Memorial Health Care Corporation (BMHCC) in Memphis, Tennessee. This relationship was…
CURRENT ISSUE
Volume XXXI, No. 13 – September 23, 2024
The Dark Report has visited several companies in Europe to see what innovations they have developed that might be coming to laboratories and pathology groups in the U.S. Also, hospital lab outreach businesses are still valuable commodities in the eyes of the Blood Brothers. In addition, The Dark Report delivers the 2nd quarter earnings reports of the top global IVD companies.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized